TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7917739
Drug: Ornipressin 10(‐4)
Normalized name: ornipressin
DrugBank: Ornipressin (DB13464)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ornipressin 10(‐4) u. ml‐1
Study: 7917739
Drug: Ornipressin 10(‐2)
Normalized name: ornipressin
DrugBank: Ornipressin (DB13464)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ornipressin 10(‐2) u. ml‐1
Study: 7917739
Drug: Ornipressin 10(‐1)
Normalized name: ornipressin
DrugBank: Ornipressin (DB13464)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ornipressin 10(‐1) u. ml‐1
Study: 7917739
Drug: Ornipressin 10(0)
Normalized name: ornipressin
DrugBank: Ornipressin (DB13464)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ornipressin 10(0) u. ml‐1
Study: 7917739
Drug: Ornipressin 10(‐3)
Normalized name: ornipressin
DrugBank: Ornipressin (DB13464)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ornipressin 10(‐3) to 10(‐1) u. ml‐1
Study: 3293456
Drug: Hydroxyurea (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (80 mg/kg each Monday and Thursday during external radiation therapy)
Study: 29696684
Drug: Fostamatinib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostamatinib (100 mg BID for 24 weeks, increased to 150 mg BID for nonresponders after 4 weeks)
Study: 26653203
Drug: Self-testing (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-testing (4 oral-fluid self-test kits at enrolment, additional kits on request)
Study: 18192839
Drug: ACEIs (Angiotensin-Converting
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEIs (Angiotensin-Converting Enzyme Inhibitors) administered for 6 weeks
Study: 16704648
Drug: Two-compound product
Normalized name: Ceo-Two Rectal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-compound product (Dovobet/Daivobet/Taclonex) for 52 weeks
Study: 16704648
Drug: Alternating group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating group (two-compound product and calcipotriol for 52 weeks)
Study: 16704648
Drug: Calcipotriol for
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol for 48 weeks after 4 weeks of the two-compound product
Study: 16704648
Drug: Two-compound product
Normalized name: Ceo-Two Rectal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-compound product vs Calcipotriol
Study: 16704648
Drug: Two-compound product
Normalized name: Ceo-Two Rectal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-compound product
Study: 15581966
Drug: High-dose intraarterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intraarterial infusion chemotherapy under percutaneous pelvic perfusion with extracorporeal chemofiltration (PPPEC) using high-dose cisplatin alone (140-250 mg/m2) or high-dose cisplatin plus mitomycin C (7 mg/m2), pepleomycin (7 mg/m2) and 5-fluorouracil (700 mg/m2)
Study: 10945313
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice with 5 mg felodipine
Study: 10945313
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice with 2.5 mg felodipine for 2 days followed by 5 mg felodipine for 6 days
Study: 10945313
Drug: Water with
Normalized name: sterile water with electrolytes injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water with 5 mg felodipine
Study: 10945313
Drug: Water with
Normalized name: sterile water with electrolytes injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water with 2.5 mg felodipine for 2 days followed by 5 mg felodipine for 6 days
Study: 8405008
Drug: Pravastatin 5
Normalized name: pravastatin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 5 mg/day (Group 1)
Study: 8405008
Drug: Pravastatin 10
Normalized name: pravastatin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 10 mg/day (Group 2)
Study: 8405008
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (both groups)
Study: 30219475
Drug: Hydroalcoholic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroalcoholic extract of M. officinalis (HEMO) (700 mg/d)
Study: 25747955
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg omega-3 fatty acid supplements (containing 180 mg eicosapentaenoic acid and 120 mg docosahexanoic acid)
Study: 25576353
Drug: Bevacizumab +
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab + chemotherapy
Study: 10942228
Drug: Low-dose cytarabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cytarabine (LDAC), 10 mg/m2 subcutaneously twice a day for 21 days every 2 months until relapse.
Study: 10942228
Drug: Observation (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation (no additional therapy).
Study: 10942228
Drug: Low-dose cytarabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cytarabine (LDAC).
Study: 1578935
Drug: Prolonged intensive
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prolonged intensive chemotherapy
Study: 3922936
Drug: Aztreonam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aztreonam (1 or 2 g intramuscular injections for ten days)
Study: 29193747
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg cherry-flavored mini lozenge
Study: 29193747
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg cherry-flavored mini lozenge
Study: 29193747
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg mint-flavored mini lozenge
Study: 29193747
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg mint-flavored mini lozenge
Study: 26354927
Drug: Procarbazine/lomustine/vincristine (PCV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procarbazine/lomustine/vincristine (PCV) chemotherapy
Study: 23761303
Drug: Zoledronate 1
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronate 1 mg
Study: 23761303
Drug: Zoledronate 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoledronate 2.5 mg
Study: 19952950
Drug: Low-dose interferon-alpha
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose interferon-alpha 2a
Study: 16177249
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of azithromycin orally
Study: 16177249
Drug: 2.4 million
Normalized name: penicillin G benzathine 2.4 million unit INTRAMUSC VIAL (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 million units of penicillin G benzathine intramuscularly
Study: 11929348
Drug: Salmeterol/fluticasone propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone propionate combination (SFC) 50/100microg, administered twice daily via inhaler for 12 weeks
Study: 11929348
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 100microg, administered twice daily via inhaler for 12 weeks
Study: 28604133
Drug: Topical cetirizine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cetirizine 1%
Study: 26892849
Drug: Eye movement
Normalized name: JOINT MOVEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye movement desensitisation and reprocessing (EMDR) therapy (12 hours total: 3×60 min planning/preparation followed by 6×90 min desensitisation/reprocessing)
Study: 26892849
Drug: Stabilisation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stabilisation therapy (12 hours total: 12×60 min)
Study: 23842081
Drug: Milk-fat from
Normalized name: MILK FAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk-fat from mountain-pasture grazing cows (G)
Study: 21731996
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine with midazolam (3 mL 0.5% bupivacaine and 0.4 mL (2 mg) midazolam)
Study: 21731996
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine without midazolam (3 mL 0.5% bupivacaine with 0.4 mL saline)
Study: 19362014
Drug: Cohen blocker
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohen blocker
Study: 19499865
Drug: Arndt blocker
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arndt blocker
Study: 19362014
Drug: Cohen blocker
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohen blocker (left bronchus occlusion)
Study: 19362014
Drug: Cohen blocker
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohen blocker (right bronchus occlusion)
Study: 19362014
Drug: All blockers
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All blockers
Study: 19362014
Drug: Cohen blocker
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohen blocker and Arndt blocker
Study: 17081282
Drug: Intravenous trace
Normalized name: Trace metal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous trace element supplements (copper 2.5 to 3.1 mg/day, selenium 315 to 380 µg/day, zinc 26.2 to 31.4 mg/day) for 8 to 21 days
Study: 17081282
Drug: Intravenous trace
Normalized name: Trace metal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous trace element supplements
Study: 15471833
Drug: 99mTc‐labeled ethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99mTc‐labeled ethylene dicysteine (EC) C225 administered before 20 mg test dose
Study: 15471833
Drug: 99mTc‐labeled ethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99mTc‐labeled ethylene dicysteine (EC) C225 administered after 400 mg/m2 loading dose of unlabeled C225
Study: 9266270
Drug: Ampicillin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin (1 g)/Sulbactam (0.5 g)
Study: 9266270
Drug: Cefotiam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotiam (2 g)
Study: 8119065
Drug: Diet treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet treatment (control-assigned group)
Study: 6480455
Drug: Dexamethasone (DEXA)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEXA) 2 mg t.i.d. during treatment
Study: 30125052
Drug: Epanova 4
Normalized name: Epanova
DrugBank: Omega-3-carboxylic acids (DB09568)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epanova 4 g daily
Study: 19552598
Drug: Xuezhikang (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhikang (1200 mg/d)
Study: 15048162
Drug: Early goal
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early goal directed therapy
Study: 15048162
Drug: Moderate doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate doses of steroids
Study: 8725851
Drug: Miglitol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miglitol (50 mg three times daily)
Study: 1340780
Drug: Ephedrine 50
Normalized name: Ephedrine 50 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 50 mg
Study: 498825
Drug: Ephedrine 25
Normalized name: ephedrine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 25 mg
Study: 6726466
Drug: Maternal pyridoxine
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal pyridoxine X HCl (PN‐HCl) supplementation at 7.5 mg or more
Study: 6726466
Drug: Maternal pyridoxine
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal pyridoxine X HCl (PN‐HCl) supplementation at 7.5 mg and greater
Study: 6726466
Drug: Maternal pyridoxine
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal pyridoxine X HCl (PN‐HCl) supplementation at 7.5 mg
Study: 6726466
Drug: Vitamin B-6
Normalized name: Vitamin B-6 100mg Tablet
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B-6 intake between 5.5 and 7.6 mg/day (diet plus supplement as pyridoxine equivalents)
Study: 19332958
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg plus amlodipine 10 mg
Study: 19332958
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg (monotherapy)
Study: 19332958
Drug: Telmisartan 40
Normalized name: telmisartan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 40 mg plus amlodipine 10 mg
Study: 16537682
Drug: saline/ghrelin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline/ghrelin infusion
Study: 16537682
Drug: l-arginine/saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-arginine/saline
Study: 16537682
Drug: l-arginine/ghrelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-arginine/ghrelin
Study: 12683264
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics (except amisulpride)
Study: 8622332
Drug: Alpha-tocopherol (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-tocopherol (800 IU daily for first 546 patients; 400 IU daily for remainder)
Study: 1391111
Drug: Conventional diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional diet administered to 21 patients
Study: 1391111
Drug: Commercial enteral
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial enteral diet administered to 28 patients
Study: 6399448
Drug: General treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: General treatment program for alcoholism including relaxation training
Study: 24568148
Drug: Myoelectric simulator
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Myoelectric simulator training (combination of tasks)
Study: 22321357
Drug: 1.62% testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.62% testosterone gel (Continuing Active subjects)
Study: 22321357
Drug: 1.62% testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.62% testosterone gel (Formerly Placebo subjects)
Study: 18004138
Drug: Venlafaxine 37.5
Normalized name: venlafaxine 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 37.5 mg BID for 7 days followed by 75 mg BID for another 7 days
Study: 9744643
Drug: rBPI21 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: rBPI21 administered by continuous intravenous infusion for 48 hours in patients and healthy volunteers
Study: 9744643
Drug: rBPI21 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: rBPI21 administered intravenously in rats after 60% or 80% hepatectomy
Study: 9744643
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered to healthy volunteers
Study: 3054591
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with preoperative radiotherapy (4 Gy for 5 days, total 20 Gy)
Study: 3054591
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with preoperative radiotherapy
Study: 28500492
Drug: Methylprednisolone 500
Normalized name: methylprednisolone 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 500 mg i.v.
Study: 28500492
Drug: Paracetamol 4
Normalized name: Paracetamol 48.2 mg/mL oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 4 g i.v.
Study: 28500492
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (Methylprednisolone, Paracetamol, Placebo)
Study: 26135245
Drug: Investigational MenABCWY
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational MenABCWY vaccine formulations (2 doses)
Study: 26135245
Drug: Investigational MenABCWY
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational MenABCWY vaccine formulations (3 doses)
Study: 26135245
Drug: Investigational MenABCWY
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational MenABCWY vaccines (2 or 3 doses)
Study: 26135245
Drug: Investigational MenABCWY
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational MenABCWY vaccines
Study: 21452294
Drug: Atacicept 150
Normalized name: Atacicept
DrugBank: Atacicept (DB06399)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atacicept 150 mg weekly (with or without a 4-week loading period)
Study: 12900133
Drug: High-dose magnesium
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose magnesium and low-dose lidocaine, infused over 3 days
Study: 10875098
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment (ampicillin)
Study: 7956612
Drug: Propranolol (30-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (30-60 mg/day)
Study: 2852692
Drug: Metoclopramide (MCP)
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide (MCP) 10 mg iv
Study: 2852692
Drug: Domperidone (DMP)
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (DMP) 10 mg iv
Study: 27567243
Drug: Intravenous glyburide
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glyburide
Study: 27537707
Drug: Non-Hoarding Community
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Hoarding Community Controls (CC)
Study: 22460947
Drug: Intensive consolidation
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive consolidation therapy (high-dose cytarabine combined with amsacrine or daunorubicin)
Study: 22460947
Drug: Standard consolidation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard consolidation and maintenance therapy (standard dose cytarabine and daunorubicin)
Study: 22460947
Drug: Intensive consolidation
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive consolidation therapy
Study: 22460947
Drug: Standard consolidation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard consolidation and maintenance therapy
Study: 9498258
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin 2 x 100 U/kg/d s.c. for 4 weeks (n = 90)
Study: 9498258
Drug: Ticlopidine 2
Normalized name: ticlopidine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine 2 x 250 mg/d and low molecular weight heparin 2 x 100 U/kg/d s.c. for 4 weeks (n = 72)
Study: 9498258
Drug: Ticlopidine 2
Normalized name: ticlopidine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine 2 x 250 mg/d for 4 weeks (n = 125)
Study: 9498258
Drug: Anticoagulant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant therapy (phenprocoumon and low molecular weight heparin)
Study: 9498258
Drug: Phenprocoumon and
Normalized name: phenprocoumon
DrugBank: Phenprocoumon (DB00946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenprocoumon and low molecular weight heparin
Study: 2695866
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral contraceptive containing cyproterone acetate
Study: 2695866
Drug: Other low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Other low-dose oral contraceptives (desogestrel, gestodene)
Study: 340141
Drug: Pentazocine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine (15 mg) plus Paracetamol (500 mg)
Study: 340141
Drug: Dextropropoxyphene hydrochloride
Normalized name: Dextropropoxyphene hydrochloride
DrugBank: Dextropropoxyphene (DB00647)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextropropoxyphene hydrochloride (32.5 mg) plus Paracetamol (325 mg)
Study: 21488750
Drug: OROS methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS methylphenidate (MPH) 18-54 mg/day
Study: 17689968
Drug: Vancomycin (VAN)
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin (VAN) 15 mg/kg
Study: 17689968
Drug: Teicoplanin (TEC)
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (TEC) 8 mg/kg
Study: 10643541
Drug: EPOCH regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPOCH regimen (etoposide 50 mg/m2, vincristine 0.4 mg/m2, doxorubicin 10 mg/m2 continuous infusion days 1-4; cyclophosphamide 750 mg/m2 i.v. bolus day 6; prednisone 60 mg/m2 days 1-6)
Study: 7605854
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg p.o. daily
Study: 7605854
Drug: Lansoprazole 60
Normalized name: dexlansoprazole 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 60 mg p.o. daily
Study: 7605854
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg p.o. b.d.
Study: 23478059
Drug: Abagovomab 2
Normalized name: Abagovomab
DrugBank: Abagovomab (DB16077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abagovomab 2 mg administered as 1‐mL suspension once every 2 weeks for 6 weeks (induction phase) and then once every 4 weeks (maintenance phase) until recurrence or up to 21 months after random assignment of the last patient.
Study: 23478059
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as 1‐mL suspension once every 2 weeks for 6 weeks (induction phase) and then once every 4 weeks (maintenance phase) until recurrence or up to 21 months after random assignment of the last patient.
Study: 16458970
Drug: Sub-Tenon's capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-Tenon's capsule injection of 20 mg triamcinolone acetonide (TA)
Study: 16458970
Drug: Control eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control eye (no TA injection)
Study: 11966483
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion (starting at 1 mIU/min, increasing every 30 minutes up to 30 mIU/min)